Radar Therapeutics Announces $13.4M Seed financing

Gunderson Dettmer represented client Radar Therapeutics, a biotech company developing programmable precision therapeutics, in its $13.4 million Seed financing led by NfX Ventures. Leveraging innovative mRNA technology, the company aims to revolutionize medicine by enabling targeted, timely, and controlled therapeutic interventions.

In the announcement of the transaction, Radar Therapeutics Co-Founder and CEO Sophia Lugo said, “We can selectively write a function into any cell type. Programmable mRNA-based therapies have the potential to be in vivo, scalable and modular, to improve patient access. We’re thrilled to have the support of these top-tier investors as we advance our preclinical programs.”

The Gunderson Dettmer deal team was led by Mike Allers and included Nate Gray, Ben Adler, Gina Marek, Julie Mahoney and Will Bassett.

Companies
Radar Therapeutics
NFX Ventures